Hebei Changshan Biochem Pharma Financial Flexibility Index
Hebei Changshan Biochem Pharma financial flexibility index. Hebei Changshan Biochem Pharma (300255) has a Financial Flexibility Index of 0.00x as of September 2025. Free cash flow of CN¥-6.39 Million (operating CF CN¥-30.86 Million minus capex CN¥24.47 Million) represents 0% of total liabilities (CN¥3.18 Billion). See Hebei Changshan Biochem Pharma free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Hebei Changshan Biochem Pharma (2008–2024)
Financial flexibility index of Hebei Changshan Biochem Pharma from 2008 to 2024. Historical Financial Flexibility Index trend for Hebei Changshan Biochem Pharma across 17 annual periods. Check 300255 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Hebei Changshan Biochem Pharma Financial Flexibility Index by Year (2008–2024)
Hebei Changshan Biochem Pharma financial flexibility index by year from 2008 to 2024. Year-by-year free cash flow to debt coverage for Hebei Changshan Biochem Pharma. For the full cash flow conversion analysis, see Hebei Changshan Biochem Pharma cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.10x | CN¥295.81 Million | CN¥56.22 Million | CN¥2.99 Billion | ▲ +1.4% |
| 2023 | 0.10x | CN¥273.05 Million | CN¥33.73 Million | CN¥2.80 Billion | ▼ -33.0% |
| 2022 | 0.15x | CN¥434.35 Million | CN¥3.13 Million | CN¥2.98 Billion | ▼ -0.8% |
| 2021 | 0.15x | CN¥310.95 Million | CN¥2.87 Million | CN¥2.12 Billion | ▲ +1458.4% |
| 2020 | 0.01x | CN¥16.20 Million | CN¥-183.58 Million | CN¥1.72 Billion | ▼ -89.1% |
| 2019 | 0.09x | CN¥105.28 Million | CN¥-58.13 Million | CN¥1.22 Billion | ▼ -78.4% |
| 2018 | 0.40x | CN¥527.65 Million | CN¥292.81 Million | CN¥1.32 Billion | ▲ +36.3% |
| 2017 | 0.29x | CN¥320.58 Million | CN¥162.28 Million | CN¥1.09 Billion | ▼ -8.1% |
| 2016 | 0.32x | CN¥268.48 Million | CN¥171.96 Million | CN¥842.59 Million | ▲ +411.0% |
| 2015 | 0.06x | CN¥47.20 Million | CN¥-38.14 Million | CN¥757.07 Million | ▼ -41.8% |
| 2014 | 0.11x | CN¥66.24 Million | CN¥-84.97 Million | CN¥617.87 Million | ▼ -84.7% |
| 2013 | 0.70x | CN¥251.96 Million | CN¥-15.24 Million | CN¥359.78 Million | ▲ +274.5% |
| 2012 | 0.19x | CN¥54.75 Million | CN¥-70.62 Million | CN¥292.77 Million | ▼ -21.7% |
| 2011 | 0.24x | CN¥47.47 Million | CN¥17.04 Million | CN¥198.78 Million | ▼ -24.5% |
| 2010 | 0.32x | CN¥66.80 Million | CN¥29.25 Million | CN¥211.25 Million | ▼ -29.8% |
| 2009 | 0.45x | CN¥48.26 Million | CN¥24.21 Million | CN¥107.15 Million | ▲ +259.9% |
| 2008 | -0.28x | CN¥-29.05 Million | CN¥-30.83 Million | CN¥103.16 Million | — |